Monument Therapeutics Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis
Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis.
ZeroRISC Delivers Production-Grade Post-Quantum Cryptography for Open Silicon
ZeroRISC has delivered a production-grade, open-source cryptographic hardware and software stack designed to secure systems in a post-quantum computing era, stemming from a multi-year collaboration with the Max Planck Institute for Security and Privacy and the Institute of Information Science at Academia Sinica.
Engine vroom as Abselion opens US base
Abselion, a life sciences tech company anchored in Cambridge UK and focused on simplifying biomolecule quantification, has established a US subsidiary at The Engine in Cambridge, MA.
CamGene Therapeutics wins HCR Law Impact55 accolade
CamGene Therapeutics, based in Hauxton, has won the HCR Law Impact55 title. The company uses biotechnology to develop medicines that aim to treat hearing loss rather than simply manage it.
Eco-Inject raises £5.2m to scale reinvented autoinjector
Eco-Inject, a Cambridge Science Park medical device company reinventing the autoinjector, has completed a £5.2 million equity raise led by British investment syndicate, Adjuvo and is targeting a significant slice of a huge international market.
Axol Bioscience makes third acquisition in five years
Axol Bioscience, a life science business headquartered in Edinburgh but with facilities at Babraham Research Campus in Cambridge, has made a key acquisition not long after raising $2.8 million.
UK medtech Orthofuse raises £2.2M for 3D-printed implants that surgeons can tweak
London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.
Albotherm, CPI lead £2 million collaborative project to scale low-emissions greenhouse technology for UK growers
London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.
Qkine Limited and Akron Bio Announce Strategic Partnership
Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics.
Psyomics launches beseen for neurodiversity in collaboration with Mids Partnership University NHS
Psyomics has launched beseen for neurodiversity, a new digital tool that supports NHS services struggling to meet the demand of neurodevelopmental referrals and backlogs.
mOm Incubators Receives FDA Clearance for First-of-its-Kind Portable Incubator for Premature Babies
Unique, easy-to-use lightweight incubator enables care anywhere and everywhere while avoiding separation of mother and baby
Potential for novel incubator to address key aspects of preterm neonatal care and reduce dependence on NICU
Axol Bioscience secures $2.8m funding
Axol Bioscience, which has facilities in Cambridge and Edinburgh, has raised $2.8 million (£2.1m) funding to accelerate product development, scale up cell manufacturing and progress US expansion plans.
OXFORD SPACE SYSTEMS AND SSTL ANNOUNCE SUCCESSFUL LAUNCH OF CARBSAR IOD SATELLITE
Oxford Space Systems and Surrey Satellite Technology Ltd (SSTL) have announced the successful launch of CarbSAR IOD, SSTL’s latest Synthetic Aperture Radar (SAR) technology demonstration satellite incorporating Oxford Space Systems’ innovative Wrapped Rib Antenna. The spacecraft was launched aboard a Falcon 9 rocket operated by SpaceX from Vandenberg Space Force Base, California.
Nova Pangaea Technologies Appoints New CEO to Lead Global Growth
Nova Pangaea Technologies, the sustainable aviation fuel specialist backed by International Airlines Group, has appointed veteran cleantech leader Stewart Stewart as CEO.
CyberSmart joins NCRCG to support SMEs and MSPs
The National Cyber Resilience Centre Group (NCRCG) has welcomed CyberSmart as a National Ambassador to support UK SMEs and MSPs in strengthening cyber-resilience.
Oxford Drug Design reports major in vivo milestone for novel cancer therapy
Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, marking a significant step forward for the Oxford-based AI drug discovery company.
Qureight appoints Rebecca Simmons as Chief Operating Officer
Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Rebecca Simmons as Chief Operating Officer.
Qureight appoints Dr Steven Bishop as Chief Medical Officer
Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Dr Steven Bishop as Chief Medical Officer (CMO). Previously Chief Data Officer, Steven’s new role reflects changes in company structure, in response to continued growth and commercial success.
Ones to Watch - North East companies tipped for greatness in 2026
In the last of our end-of-year pieces, business writers Coreena Ford and Tom Keighley pick their five companies to watch in 2026
New trial for Walsall heart failure patients
Heart failure patients are being sought by Walsall researchers to take part in a trial to test a new device aimed at preventing deterioration and helping them avoid hospital admission.